FORT WORTH, Texas, Oct. 29 /PRNewswire-FirstCall/ -- Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM) announced today that the company is currently negotiating with several organizations looking to license WMT's proprietary activated collagen products for wound care management outside the United States.
"Wound Management Technologies has been working with various medical professionals to demonstrate how and why WMT's collagen products significantly outperform other collagen products on the market today. The positive results we have received from these demonstrations has generated both national and international interest and has provided us with the opportunity to bring in wound care organizations in different regions of the world as business partners," said Scott Haire, the company's Chief Executive Officer.
From a worldwide perspective, wound care is a $20 billion plus health care expenditure, explains the company's Chief Operations Officer, Bobby Stout. Stout added "We continue to examine existing and future partner relationships as a means to be able to achieve and maximize our revenues. By releasing additional evidence based studies and performing more clinical research, we believe we will continue to demonstrate why WMT's activated collagen products produce the best results on diabetic wounds, as well as other patients requiring wound management." CellerateRx(R), WMT's current activated collagen product, is FDA cleared for use on all wound types, except for 3rd degree burns and is effective in all wound phases.
Evidence of the efficacy of WMT's activated collagen was recently
presented at the 9th annual New Cardiovascular Horizons (NCVH) and
Management of the Diabetic Foot and Wound Healing conference, held
September 10-13, 2008 in New Orleans. NCVH is one of the largest
international multi-disciplinary conferences. The presentation was on
Friday, September 12, 2008 during the session 2nd Annual New Therapeutic
Wound Care Technology Summit: Emerging Use of Topical "Biologics" in Limb
Salvage--Role of "Activated Collagen" in Multimodality Treatment. The
entire presentation can be seen on the WMT's web site or using these links
Please click here to view Presentation:
For ALL presentations of the NCVH 2008 conference, click here:
Wound Management Technologies, Inc., also announced today that its subsidiary, Wound Care Innovations, LLC, will exhibit at the 23rd Annual Clinical Symposium on Advances in Skin and Wound Care: The Conference for Prevention and Healing at the Rio All Suite Hotel in Las Vegas, Nevada. The Symposium is designed to enable the attendee to apply basic to advanced concepts in the science of wound healing or in preventing and managing wounds. Presented will be cutting-edge treatments, emerging technologies, and research breakthroughs which will assist clinicians in identifying credible, balanced, and relevant clinical practice issues.
"This conference is an excellent opportunity for us to present our advanced wound care product, CellerateRx(R)" states Cathy Bradshaw, President of Wound Care Innovations. "We are especially excited about this conference as there were case reports using CellerateRx(R) in the August issue of the wound care journal, Advances in Skin & Wound. The Symposium allows us to target key wound care specialists from all around the United States and international attendees as well."
About Wound Management Technologies, Inc.:
Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM), with its corporate headquarters in Fort Worth, Texas, markets and distributes wound care products to the healthcare market under patented technology licensed to the Company. The Company is positioned and seeks to be a leading provider of wound care products. For more information on the Company please visit the Company's Website at: http://www.Celleraterx.com
"Safe Harbor" Statement: Under The Private Securities Litigation Reform
Act of 1995: The statements in the press release that relate to the
company's expectations with regard to the future impact on the company's
results from new products in development are "forward-looking statements,"
within the meaning of the Private Securities Litigation Reform Act of 1995.
Since this information may contain statements that involve risk and
uncertainties and are subject to change at any time, the company's actual
results may differ materially from expected results. This document may
contain forward-looking statements concerning the Company's operations,
current and future performance and financial condition. These items involve
risks and uncertainties such as product demand, market and customer
acceptance, the effect of economic conditions, competition, pricing, the
ability to consummate and integrate acquisitions, and other risks and
uncertainties detailed in the Company's SEC filings. The Company undertakes
no obligation to revise any of these statements to reflect the future
circumstances or the occurrence of unanticipated events.
For Further Information:
Product Information Shareholder Relations
Cathy Bradshaw Lucy Singleton
|SOURCE Wound Management Technologies, Inc.|
Copyright©2008 PR Newswire.
All rights reserved